anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This delayed intervention group will receive the adapted intervention, "Heart Matters," six months after the T1 Intervention group. The intervention will be 12 months long.
Women randomised to the experimental arm / individualised screening will have their 2-year breast cancer risk assessed upfront. This is done via an AI (artificial intelligence) derived analyses of the mammograms. Women scored with the highest 2-year risk will be offered a contrast enhanced mammography and an additional mammography at 12 months.
The invention discloses a BCMA (brain cell activating antigen) -targeted antibody, a BCMA and CD 3-targeted bispecific antibody and application thereof. The BCMA-targeting antibody comprises two heavy chain variable regions comprising the amino acid sequences set forth in SEQ ID NOs: 22. SEQ ID NO: 33. SEQ ID NO:42, HCDR1, HCDR2, HCDR 3; or as shown in SEQ ID NO: 26. SEQ ID NO: 37. SEQ ID NO:41 of HCDR1, HCDR2 and HCDR 3. The antibody of the invention effectively targets human BCMA and combines with cynomolgus monkey BCMA; bispecific antibodies effectively target both human BCMA and human CD3, and are capable of binding cynomolgus monkey BCMA and cynomolgus monkey CD 3.
1462718 Digoxin complexes INTERX RESEARCH CORP 27 June 1974 [29 June 1973] 28531/74 Heading C2U The invention comprises complexes of formula where D is digoxin, A is a dihydroxybenzene, and n is 1, 1¢ or 2; and their preparation by contacting D and A in a solvent (e.g. water) preferably in the absence of oxygen and presence of an antioxidant (e.g. sodium bisulphite) until the complex precipitates (with the aid of seeding if necessary). Purification of digoxin is effected by forming and isolating a complex as above, contacting the complex with a suitable solvent (e.g. water or diethyl ether) and isolating precipitated digoxin. Oral cardiotonic compositions comprise a complex as above and a carrier and optionally also a dihydroxybenzene or antinucleating agent.
The aim of this narrative review was to provide an overview of what is known about the health care transition process in pediatric chronic pain, barriers to successful transition of care, and the roles that pediatric psychologists and other health care providers can play in the transition process. Searches were run in in Ovid, PsycINFO, Academic Search Complete, and PubMed. Eight relevant articles were identified. There are no published protocols, guidelines, or assessment measures specific to the health care transition in pediatric chronic pain. Patients report many barriers to the transition process, including difficulty attaining reliable medical information, establishing care with new providers, financial concerns, and adapting to the increased personal responsibility for their medical care. Additional research is needed to develop and test protocols to facilitate transition of care. Protocols should emphasize structured, face-to-face interactions and include high levels of coordination between pediatric and adult care teams.
Despite research efforts being made towards preserving (or even regenerating) heart tissue after an ischemic event, there is a lack of resources in current clinical treatment modalities for patients with acute myocardial infarction that specifically address cardiac tissue impairment. Modified messenger RNA (modRNA) presents compelling properties that could allow new therapeutic strategies to tackle the underlying molecular pathways that ultimately lead to development of chronic heart failure. However, clinical application of modRNA for the heart is challenged by the lack of effective and safe delivery systems. Lipid nanoparticles (LNPs) represent a well characterized class of RNA delivery systems, which were recently approved for clinical usage in mRNA-based COVID-19 vaccines. In this study, we evaluated the potential of LNPs for cardiac delivery of modRNA. We tested how variations in C12-200 modRNA-LNP composition affect transfection levels and biodistribution after intramyocardial administration in both healthy and myocardial-infarcted mice, and determined the targeted cardiac cell types. Our data revealed that LNP-mediated modRNA delivery outperforms the current state of the art (modRNA in citrate buffer) upon intramyocardial administration in mice, with only minor differences among the formulations tested. Furthermore, we determined both in vitro and in vivo that the cardiac cells targeted by modRNA-LNPs include fibroblasts, endothelial cells and epicardial cells, suggesting that these cell types could represent targets for therapeutic interference with these LNP formulations. These outcomes may serve as a starting point for LNP development specifically for therapeutic mRNA cardiac delivery applications.
The present disclosure relates to automatic verification of test results. The analyzer analyzes the patient sample and then the test results are confirmed. Validation of test results may be performed remotely over a network or performed at a local computer. For example, although a network communication error may prevent remote confirmation, local confirmation may still be performed, which allows automatic confirmation to be performed continuously. The validation of the test results of the patient sample obtained by the analyzer may also be performed by: 1) a first rule included in a first system of a laboratory; and 2) a second rule included in a second system remotely accessible via a network. The disclosure also relates to an inspection management method based on at least one of the two rules.
CINQAIR is provided as a solution in a single-use vial for intravenous infusion only and should be prepared by a healthcare professional using aseptic technique as follows:

Preparation of intravenous infusion

  1. Remove CINQAIR from the refrigerator. To minimize foaming, do not shake CINQAIR.
  2. Inspect visually for particulate matter and discoloration prior to administration. CINQAIR solution is clear to slightly hazy/opalescent, colorless to slightly yellow liquid. Since CINQAIR is a protein, proteinaceous particles may be present in the solution that appear as translucent to white, amorphous particulates. Do not administer if discolored or if other foreign particulate matter is present.
  3. Withdraw the proper volume of CINQAIR from the vial(s), based on the recommended weight-based dosage. Discard any unused portion.
  4. Dispense syringe contents slowly into an infusion bag containing 50 mL of 0.9% Sodium Chloride Injection, USP to minimize foaming of CINQAIR (CINQAIR is compatible with polyvinylchloride (PVC) or polyolefin infusion bags). Gently invert the bag to mix the solution. Do not shake. Do not mix or dilute with other drugs.
  5. Administer immediately after preparation. If not used immediately, store diluted solutions of CINQAIR in the refrigerator at 2°C to 8°C (36°F to 46°F) or at room temperature up to 25ºC (77ºF), protected from light, for up to 16 hours. The time between preparation of CINQAIR and administration should not exceed 16 hours.



Administration instructions

  1. CINQAIR should be administered by a healthcare professional prepared to manage anaphylaxis [see Warnings and Precautions (5.1)].
  2. If refrigerated prior to administration, allow the diluted CINQAIR solution to reach room temperature.
  3. Use an infusion set with an in-line, low protein-binding filter (pore size of 0.2 micron). CINQAIR is compatible with polyethersulfone (PES), polyvinylidene fluoride (PVDF), nylon, and cellulose acetate in-line infusion filters.
  4. Infuse the diluted solution of CINQAIR intravenously, over a 20 to 50 minute period. Infusion time may vary depending on the total volume to be infused as based upon patient weight. 
  5. Do not infuse CINQAIR concomitantly in the same intravenous line with other agents. No physical or biochemical compatibility studies have been conducted to evaluate the co-administration of CINQAIR with other agents.
  6. Observe the patient over the infusion and for an appropriate period of time following infusion.
  7. Upon completion of the infusion, flush the intravenous administration set with 0.9% Sodium Chloride Injection, USP to ensure that all CINQAIR has been administered.
An inexpensive device, shown in the figure, for preparing tissue sealant is disclosed. The device is particularly applicable to preparation of autologous tissue sealant. A method of sealing tissue in which the tissue sealant is applied immediately after mixing platelet-rich plasma concentrate with a solution of calcium and thrombin is also disclosed. Adhesive and tensile strengths are comparable or superior to pooled blood fibrin sealants made with precipitation methods. Antifibrinolytic agents are not necessary because the tissue sealant contains high concentrations of natural inhibitors of fibrinolysis from the patient's blood. The tissue sealant also contains patient platelets and additional factors not present in available fibn sealants that promote wound healing:
Powdery mildew, caused by Blumeria graminis f. sp. tritici (Bgt), reduces wheat yields and grain quality, thus posing a significant threat to global food security. Wild relatives of wheat serve as valuable resources for resistance to powdery mildew. Here, the powdery mildew resistance gene Pm6Sl is cloned from the wild wheat species Aegilops longissima. It encodes a nucleotide-binding leucine-rich repeat (NLR) protein featuring a CC-BED module formed by a zinc finger BED (Znf-BED) domain integrated into the coiled-coil (CC) domain. The function of Pm6Sl is validated via mutagenesis, gene silencing, and transgenic assays. In addition, we develop a resistant germplasm harbouring Pm6Sl in a very small segment with no linkage drag along with the diagnostic gene marker pm6sl-1 to facilitate Pm6Sl deployment in wheat breeding programs. The cloning of Pm6Sl, a resistance gene with BED-NLR architecture, will increase our understanding of the molecular mechanisms underlying BED-NLR-mediated resistance to various pathogens.
The trials used for the basis of approval for calcitonin salmon injection for treatment of Paget’s disease of bone were conducted in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion. In open-label clinical trials of several months to two years duration with historical controls, biochemical abnormalities were substantially improved (more than 30% reduction) in about 2/3 of patients studied and bone pain was improved in a similar fraction. A small number of documented instances of reversal of neurologic deficits have occurred, including improvement in the basilar compression syndrome, and improvement of spinal cord and spinal nerve lesions. There is too little experience to predict the likelihood of improvement of any given neurologic lesion. Hearing loss is improved infrequently (4 of 29 patients studied by audiometry). Patients with increased cardiac output due to extensive Paget’s disease of bone have had measured decreases in cardiac output while receiving calcitonin salmon. The number of treated patients in this category is too small to predict how likely such a result will be.

There is no evidence that the prophylactic use of calcitonin salmon is beneficial in asymptomatic patients.
A 3-months study design. There will be three distinct phases: base-line testing, reading training, and follow-up testing. T1-T7 indicate the 7 time-points at which we assess the following: reading speeds (word-per-minute), visual field test, visual search test, and Activities of Daily Living rating scale (T1: Day 1, Initial assessments; T2: Day 30, Pre-training assessments; T3: Day 60, During Reading Training (RT) after 5-hours; T4: During RT after 10-hours; T5: During RT after 15-hours; T6: During RT after 20-hour; T7: Day 90, Post-training assessments). Arabic reading patients with left-sided HA will receive app-delivered reading training in a single subject control based design for 1 month.
PURPOSE:To obtain the subject pharmaceutical, containing sodium chloride and/or sugaralcohol as an additive, capable of exhibiting growth hormone releasing activity in living bodies and relieving nasal mucosal irritancy of a peptide useful in clinical medicine and usable for a long period without any toxic reaction. CONSTITUTION:A pharmaceutical containing sodium chloride and/or sugaralcohol as an additive. In use, the pharmaceutical is formed into a solution so as to enable spraying or dripping of a peptide which is an active ingredient into the nasal cavity or freeze-dried pharmaceutical from aspects of preservation stability, dissolved in a dissolving solution and employed in use. The content of the active ingredient in the pharmaceutical is normally 0.001-10wt./vol.% in an aqueous solution or suspension. Mannitol, sorbitol, etc., are cited as the sugaralcohol employed as the aforementioned additive. The amount thereof used is 0.1-30wt./vol.% in the case of the aqueous solution or suspension and the amount of the sodium chloride used is 0.01-10wt./vol.%.
BACKGROUND: Systemic corticosteroids have become the standard of care for severe to critically ill patients with coronavirus disease 2019 (COVID-19). However, the real-world efficacy and safety outcomes associated with a higher dose of corticosteroids remain uncertain.
METHODS: We conducted a nationwide, population-based, matched cohort study of severe to critically ill adult patients with COVID-19 between January 2020 and June 2021 in Korea using the National Health Information Database. Patients using systemic corticosteroids were included and high-dose corticosteroid use was defined as a daily mean prescribed dose of more than 6 mg of dexamethasone. We then employed a proportional hazard regression model to identify prognostic factors for 28-day all-cause mortality and conducted a Fine and Gray regression model to assess risk factors for developing COVID-19-associated pulmonary aspergillosis (CAPA).
RESULTS: During the study period, 102,304 patients with COVID-19 were screened, 5,754 met the eligibility criteria, and 2,138 were successfully matched. The mean prescribed daily dose was 4.2 mg and 13.4 mg in the standard- and high-dose groups, respectively, and the mean duration of use was not different between the groups. High-dose corticosteroid use independently increased all-cause mortality at 28 days (adjusted hazard ratio [aHR], 1.48; 95% confidence interval [CI], 1.25-1.76) and 90 days (aHR, 1.63; CI, 1.44-1.85) after admission. Subgroup analysis revealed a statistically significant elevation in the risk of mortality among patients using low-flow or high-flow nasal cannulas, with aHRs of 1.41 and 1.46, respectively. No significant impact of high-dose steroids was observed, even in patients who underwent mechanical ventilation at 28 days (aHR, 1.17; CI, 0.79-1.72). As a safety outcome, high-dose corticosteroid use showed an association with the development of CAPA (aHR, 2.97; 95% CI, 0.94-9.43).
CONCLUSION: Among severe to critically ill patients with COVID-19, high-dose corticosteroid use was associated with increased 28-day all-cause mortality and showed a trend toward the development of CAPA.
Cryopreserved-thawed embryo transfer cycle, with endometrial preparation using external estradiol and progesterone only. On day 1 of the transfer cycle, the patient will receive 6 mg/ day of estradiol and followed up on day 12 of the cycle, if the endometrium did not reach 8 mm, till day 15 of the cycle the dose will be increased to 8 mg/day until the endometrium is 8 or more mm. When the endometrium is ready, serum estradiol and progesterone levels are collected, then progesterone 800 mg vaginal suppository will be added and embryo transfer performed 2 to 3 days later.
A method for noninvasive treatment of diabetic retinopathy helps prevent and reverses diabetic retinopathy and other vascular retinopathies, such as diabetic macular edema for a patient. The method comprises administering at least 80 percent pure oxygen to a patient in an oxygen chamber or nasal cannula. The oxygen chamber includes light emitting diodes that emit a light having a wavelength between 630-700 nm wavelengths on the patient. The method also includes administering an anti-inflammatory agent; an anti-oxidant; at least one of the following: an amino acid, arginine, and citrulline; and an omega-3 fatty acids to the patient. In extreme cases of diabetic retinopathy, a cold laser therapy is also administered to the patient with a wavelength between 570 nanometers and 1000 nanometers. The combination of all the aforementioned treatment modalities and compositions that work to synergistically to achieve unexpected clinical results for prevention and reversal of diabetic retinopathy.
Depression, a widespread and highly heritable mental health condition, profoundly affects millions of individuals worldwide. Neuroimaging studies have consistently revealed volumetric abnormalities in subcortical structures associated with depression. However, the genetic underpinnings shared between depression and subcortical volumes remain inadequately understood. Here, we investigate the extent of polygenic overlap using the bivariate causal mixture model (MiXeR), leveraging summary statistics from the largest genome-wide association studies for depression (N = 674,452) and 14 subcortical volumetric phenotypes (N = 33,224). Additionally, we identify shared genomic loci through conditional/conjunctional FDR analyses. MiXeR shows that subcortical volumetric traits share a substantial proportion of genetic variants with depression, with 44 distinct shared loci identified by subsequent conjunctional FDR analysis. These shared loci are predominantly located in intronic regions (58.7%) and non-coding RNA intronic regions (25.4%). The 269 protein-coding genes mapped by these shared loci exhibit specific developmental trajectories, with the expression level of 55 genes linked to both depression and subcortical volumes, and 30 genes linked to cognitive abilities and behavioral symptoms. These findings highlight a shared genetic architecture between depression and subcortical volumetric phenotypes, enriching our understanding of the neurobiological underpinnings of depression.
PURPOSE: To ensure a creamy and white appearance and to make applications for cosmetics and skin treatment possible by containing specified different aliphat. acid esters in an emulsifying system for an oil-in-water emulsion comprising an oily phase dispersed in an aq. phase with the emulsifying system. CONSTITUTION: For an oil-in-water emulsion comprising an oily phase dispersed in an aq. phase with the emulsifying system, a first ester chosen from the fatty acid esters of glucose and the fatty acid esters of alkylglucose, and at least one second fatty acid ester of sucrose are respectively contained in the emulsifying system. Further, the aq. phase is set at 40-94 wt.%, the oily phase is set at 5-50 wt.%, and the emulsifying system is set at 1-10 wt.%, on the basis of the total weight of the emulsion. Further, the ratio of the first to the second esters is set within the range of 70/30-30/70. Thereby, the oil-in-water emulsion having a creamy and white appearance which can be applied for cosmetics and skin treatment is obtained.
Provided are topical analgesic gel compositions having relatively high payloads of menthol and camphor by micro-emulsion technology and methods of preparing topical analgesic gel compositions having relatively high payloads of menthol and camphor. Topical analgesic gel compositions may include from 12 to 16 wt. % menthol; from 4 to 8 wt. % camphor; from 0.1 to 2 wt. % carbomer; and 60 to 70 wt. % solvent. Topical analgesic gel compositions can have a viscosity from 60,000 to 110,000 centipoise.
BACKGROUND: Standard of care for most patients with locally advanced rectal cancer in The Netherlands consists of neoadjuvant chemoradiotherapy (nCRT) followed by resection. Enlarged lateral lymph nodes (LLNs), especially in the iliac compartment, appears to be associated with an increased risk of local recurrence. Little is known about the risk of local recurrence after nCRT.
MATERIALS AND METHODS: This study included patients with locally advanced rectal cancer and enlarged LLNs on pretreatment MRI-scan located in the internal iliac, obturator, external iliac, or common iliac compartment. Patients were treated with nCRT and response to therapy was evaluated with MRI-scan. The primary endpoint was local lateral recurrence after nCRT. Secondary endpoints included overall survival and postoperative complications.
RESULTS: Out of 260 patients treated for rectal cancer, a total of 46 patients with enlarged LLNs (18% of all patients) were included between 2012 and 2019 in 2 Dutch hospitals. No patients had lateral lymph node recurrence (LLNR) after nCRT. Only 1 patient had local recurrence of rectal cancer after radical resection during a median follow up of 3 years. Disseminated disease was seen in 12 patients and 9 patients died during follow-up, which result in an overall survival rate of 80.4%. Postoperative complications were seen in 41% of patients. There was no 90-days postoperative mortality.
CONCLUSION: Enlarged LLNs are rare after nCRT and no LLNR was found after nCRT in our study population. This could suggest that nCRT only with or without an extra radiotherapeutic boost on enlarged LLNs already reduces the risk of LLNR.
A method and system are provided for assisting a user in assigning tokens to words or text spans in a transcript of a conversation between a patient and a medical professional and forming groupings of such tokens in the transcript. The transcript is displayed on an interface of the workstation. A text span consisting of one or more words in a transcript is provided for highlighting. Another tool for assigning labels to highlighted text spans is provided. The tool includes a feature that is searchable for a set of predefined tags that are assigned to the highlighted text span. The predefined label encodes the medical entity and an attribute of the medical entity. The interface also includes tools for creating groupings of related highlighted text spans. These tools may consist of mouse actions or keyboard strokes or a combination thereof.
468,845. Hair-waving. POLLAK, J. E. (Coriolan-Ges.) Jan. 13, 1936, No. 1121. [Class 131] Relates to a method of permanent hairwaving of the type in which the hair when subjected to the action of a waving lotion and in the presence thereof is wound on a support and thereupon heated, and consists in using as the lotion a solution of a mildly acid reacting material of organic or inorganic character which is non-destructive of the hair tissue and has a pH value under working conditions between 4À5 and 7'0. Examples of substances suitable for the lotion are bisulphites, preferably in the form of their addition products with aldehydes and ketones, alum, acid lactates, and adipic acid. Stabilizers may be added such as polyhydric alcohols, polysaccharides, albmnin solutions, cellulose ethers and other synthetic mucins or any soluble viscous materials which are harmless as cosmetics. Wetting-agents may also be added.